The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Research Report 2025
Synopsis
Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market was valued at US$ 1451.8 million in 2023 and is anticipated to reach US$ 3959.6 million by 2030, witnessing a CAGR of 14.9% during the forecast period 2024-2030.
North American market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Circulating Tumor Cells (CTCs) Prognostic Technologies in Prostate Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Circulating Tumor Cells (CTCs) Prognostic Technologies include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) Prognostic Technologies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) Prognostic Technologies.
Report Scope
The Circulating Tumor Cells (CTCs) Prognostic Technologies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cells (CTCs) Prognostic Technologies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cells (CTCs) Prognostic Technologies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Segment by Type
Tumor Cell Enrichment
Tumor Cell Detection
Segment by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) Prognostic Technologies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market was valued at US$ 1451.8 million in 2023 and is anticipated to reach US$ 3959.6 million by 2030, witnessing a CAGR of 14.9% during the forecast period 2024-2030.
North American market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Circulating Tumor Cells (CTCs) Prognostic Technologies in Prostate Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Circulating Tumor Cells (CTCs) Prognostic Technologies include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) Prognostic Technologies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) Prognostic Technologies.
Report Scope
The Circulating Tumor Cells (CTCs) Prognostic Technologies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cells (CTCs) Prognostic Technologies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cells (CTCs) Prognostic Technologies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Segment by Type
Tumor Cell Enrichment
Tumor Cell Detection
Segment by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) Prognostic Technologies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Tumor Cell Enrichment
1.2.3 Tumor Cell Detection
1.3 Market by Application
1.3.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Ovarian Cancer
1.3.7 Pancreatic Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Perspective (2019-2030)
2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Region
2.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Dynamics
2.3.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Industry Trends
2.3.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Drivers
2.3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Challenges
2.3.4 Circulating Tumor Cells (CTCs) Prognostic Technologies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue
3.1.1 Global Top Circulating Tumor Cells (CTCs) Prognostic Technologies Players by Revenue (2019-2024)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue
3.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio
3.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2023
3.5 Circulating Tumor Cells (CTCs) Prognostic Technologies Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cells (CTCs) Prognostic Technologies Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cells (CTCs) Prognostic Technologies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Type
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Type (2025-2030)
5 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Application
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2019-2030)
6.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2019-2024)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2019-2030)
7.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2019-2024)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2019-2030)
8.2 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2019-2024)
8.4 Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2019-2030)
9.2 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2019-2024)
9.4 Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size (2019-2030)
10.2 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2019-2024)
10.4 Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AdnaGen
11.1.1 AdnaGen Company Detail
11.1.2 AdnaGen Business Overview
11.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.1.5 AdnaGen Recent Development
11.2 ACDBio
11.2.1 ACDBio Company Detail
11.2.2 ACDBio Business Overview
11.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.2.5 ACDBio Recent Development
11.3 Celula
11.3.1 Celula Company Detail
11.3.2 Celula Business Overview
11.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.3.5 Celula Recent Development
11.4 Epic Sciences
11.4.1 Epic Sciences Company Detail
11.4.2 Epic Sciences Business Overview
11.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.4.5 Epic Sciences Recent Development
11.5 Fluxion Biosciences
11.5.1 Fluxion Biosciences Company Detail
11.5.2 Fluxion Biosciences Business Overview
11.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.5.5 Fluxion Biosciences Recent Development
11.6 Rarecells
11.6.1 Rarecells Company Detail
11.6.2 Rarecells Business Overview
11.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.6.5 Rarecells Recent Development
11.7 Silicon Biosystems
11.7.1 Silicon Biosystems Company Detail
11.7.2 Silicon Biosystems Business Overview
11.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.7.5 Silicon Biosystems Recent Development
11.8 Vitatex
11.8.1 Vitatex Company Detail
11.8.2 Vitatex Business Overview
11.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2019-2024)
11.8.5 Vitatex Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
